

George N Dalekos

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/993460/george-n-dalekos-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187
papers

6,214
citations

41
h-index

74
g-index

197
ext. papers

7,968
ext. citations

5.6
avg. IF

5.51
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 187 | Plethora of Resistance Genes in Carbapenem-Resistant Gram-Negative Bacteria in Greece: No End to a Continuous Genetic Evolution.. <i>Microorganisms</i> , 2022 , 10, | 4.9 | 1 |
| 186 | Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , 2022 , | 13.4 | 6 |
| 185 | Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.. <i>Cell Reports Medicine</i> , 2022 , 3, 100560 | 18 | 3 |
| 184 | Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19.. <i>International Journal of Molecular Sciences</i> , 2022 , 23, | 6.3 | 3 |
| 183 | First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients.. <i>Frontiers in Immunology</i> , 2021 , 12, 798602 | 8.4 | 1 |
| 182 | Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. <i>Annals of Gastroenterology</i> , 2021 , 34, 73-79 | 2.2 | 2 |
| 181 | Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 1 |
| 180 | ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients. <i>Journal of Innate Immunity</i> , 2021 , 1-11 | 6.9 | 3 |
| 179 | An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2021 , | 13.4 | 5 |
| 178 | SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination. <i>Hepatology Communications</i> , 2021 , | 6 | 4 |
| 177 | An Immunocompetent HIV-Negative Elderly Patient with Low-Grade Fever, Generalized Lymphadenopathy, Splenomegaly, and Acute Phase Response: Do Not Forget Castleman Disease. <i>Case Reports in Infectious Diseases</i> , 2021 , 2021, 6614208 | 0.9 | |
| 176 | Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. <i>Cancers</i> , 2021 , 13, | 6.6 | 3 |
| 175 | Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. <i>European Journal of Internal Medicine</i> , 2021 , 85, 86-91 | 3.9 | 3 |
| 174 | An open label trial of anakinra to prevent respiratory failure in COVID-19. <i>ELife</i> , 2021 , 10, | 8.9 | 57 |
| 173 | Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome. <i>Liver International</i> , 2021 , 41, 1592-1599 | 7.9 | 4 |
| 172 | Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2021 , 88, 52-62 | 3.9 | 4 |
| 171 | Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100290 | 10.3 | 0 |

| | | | |
|-----|--|------|----|
| 170 | Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. <i>Journal of Hepatology</i> , 2021 , 74, 312-320 | 13.4 | 6 |
| 169 | CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. <i>Liver International</i> , 2021 , 41, 123-127 | 7.9 | 0 |
| 168 | FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases. <i>Annals of Hepatology</i> , 2021 , 22, 100285 | 3.1 | 2 |
| 167 | Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections. <i>iScience</i> , 2021 , 24, 101947 | 6.1 | 23 |
| 166 | The changing epidemiology of hepatitis B in Greece. <i>Annals of Gastroenterology</i> , 2021 , 34, 431-437 | 2.2 | 1 |
| 165 | Programmed cell death-1 and interleukin-28B polymorphisms in autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , 2021 , 4, 100126 | 4.1 | 0 |
| 164 | Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis?. <i>Journal of Translational Internal Medicine</i> , 2021 , 9, 43-51 | 3 | 3 |
| 163 | Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?. <i>Cancers</i> , 2021 , 13, | 6.6 | 4 |
| 162 | Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. <i>JHEP Reports</i> , 2021 , 3, 100321 | 10.3 | 2 |
| 161 | Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021 , 27, 1752-1760 | 50.5 | 93 |
| 160 | Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2021 , | 11.2 | 2 |
| 159 | MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19. <i>Immunobiology</i> , 2021 , 226, 152136 | 3.4 | 2 |
| 158 | Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology, The</i> , 2021 , 3, e690-e697 | 14.2 | 38 |
| 157 | Impact of genetic and environmental factors on autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , 2021 , 4, 100125 | 4.1 | 1 |
| 156 | ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study. <i>Liver International</i> , 2021 , | 7.9 | 0 |
| 155 | Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 73, 1037-1045 | 13.4 | 34 |
| 154 | Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 699-708 | 3.4 | 7 |
| 153 | Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. <i>JHEP Reports</i> , 2020 , 2, 100123 | 10.3 | 13 |

| | | | |
|-----|---|------|----|
| 152 | Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1066-1074 | 0.7 | 31 |
| 151 | NAFLD and autoimmune hepatitis: Do not judge a book by its cover. <i>European Journal of Internal Medicine</i> , 2020 , 75, 1-9 | 3.9 | 12 |
| 150 | Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 72, 1088-1096 | 13.4 | 50 |
| 149 | Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. <i>BMJ Case Reports</i> , 2020 , 13, | 0.9 | 2 |
| 148 | Severe Pharyngodynia Followed by Migratory Polyarthritits and High Fever in Young Immigrants: Remember That Rheumatic Fever Is Still Relevant in 2020!. <i>Case Reports in Infectious Diseases</i> , 2020 , 2020, 8854868 | 0.9 | |
| 147 | 521. Similarities and Differences in Transcriptomic Host Response between SARS-CoV-2 and Other Viral Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S326-S327 | 1 | |
| 146 | Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. <i>World Journal of Gastroenterology</i> , 2020 , 26, 5130-5145 | 5.6 | 11 |
| 145 | PSC-AIH Overlap 2020 , 359-373 | | |
| 144 | Hepatic brucelloma: a rare complication of a common zoonotic disease. <i>BMJ Case Reports</i> , 2020 , 13, | 0.9 | |
| 143 | p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 52-60 | 3.4 | |
| 142 | Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 118-126 | 3.4 | 20 |
| 141 | Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar. <i>Liver International</i> , 2020 , 40, 368-376 | 7.9 | 11 |
| 140 | Linking genetic variation with epigenetic profiles in Sjögren's syndrome. <i>Clinical Immunology</i> , 2020 , 210, 108314 | 9 | 6 |
| 139 | aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020 , 73, 1368-1378 | 13.4 | 41 |
| 138 | Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1359-1368 | 3.4 | 14 |
| 137 | JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2020 , 58, 182-193 | 12.3 | 18 |
| 136 | Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 684-692.e6 | 6.9 | 10 |
| 135 | Features and outcome of AIH patients without elevation of IgG. <i>JHEP Reports</i> , 2020 , 2, 100094 | 10.3 | 9 |

| | | | |
|-----|---|------|----|
| 134 | The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019 , 105, 102328 | 15.5 | 45 |
| 133 | Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis.. <i>Epigenomes</i> , 2019 , 3, | 2.3 | 3 |
| 132 | Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 528-536 | 6.1 | 21 |
| 131 | Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019 , 67, 197-211 | 4 | 8 |
| 130 | Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2076-2084. | 6.9 | 27 |
| 129 | Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. <i>BMJ Case Reports</i> , 2019 , 12, | 0.9 | 2 |
| 128 | Aiming towards hepatitis C virus elimination in Greece. <i>Annals of Gastroenterology</i> , 2019 , 32, 321-329 | 2.2 | 5 |
| 127 | Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?. <i>Liver Transplantation</i> , 2019 , 25, 1588-1589 | 4.5 | 4 |
| 126 | Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1127-1136 | 6.1 | 29 |
| 125 | FRI-029-Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander?. <i>Journal of Hepatology</i> , 2019 , 70, e396-e397 | 13.4 | 6 |
| 124 | Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and Immunglobulin infusions. <i>World Journal of Clinical Cases</i> , 2019 , 7, 3394-3406 | 1.6 | 4 |
| 123 | Management of Patients with Liver Cirrhosis and Invasive Bladder Cancer: A Case-series. <i>Journal of Translational Internal Medicine</i> , 2019 , 7, 29-33 | 3 | 6 |
| 122 | JAK Inhibitors and Oxidative Stress Control. <i>Frontiers in Immunology</i> , 2019 , 10, 2814 | 8.4 | 18 |
| 121 | Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019 , 43, e25-e32 | 2.4 | 4 |
| 120 | Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. <i>Hepatology Research</i> , 2019 , 49, 96-104 | 5.1 | 34 |
| 119 | Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. <i>Annals of Gastroenterology</i> , 2019 , 32, 1-23 | 2.2 | 25 |
| 118 | Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018 , 68, 1129-1136 | 13.4 | 64 |
| 117 | Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , 2018 , 38, 842-850 | 7.9 | 41 |

| | | | |
|-----|--|------|-----|
| 116 | DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. <i>Antiviral Therapy</i> , 2018 , 23, 677-685 | 1.6 | 43 |
| 115 | Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia. <i>Annals of Gastroenterology</i> , 2018 , 31, 123-126 | 2.2 | 4 |
| 114 | A chronic alcoholic man with high fever, neck rigidity and loss of consciousness: remember the Austrian syndrome a commonly unrecognised invasive pneumococcus triad. <i>BMJ Case Reports</i> , 2018 , 2018, | 0.9 | 0 |
| 113 | Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018 , 113, 254-264 | 0.7 | 44 |
| 112 | Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018 , 67, 1920-1930 | 11.2 | 35 |
| 111 | Rifampicin: not always an innocent drug. <i>BMJ Case Reports</i> , 2018 , 11, | 0.9 | 1 |
| 110 | Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis. <i>Case Reports in Hepatology</i> , 2018 , 2018, 9793868 | 0.9 | 6 |
| 109 | COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. <i>European Journal of Internal Medicine</i> , 2017 , 38, 83-88 | 3.9 | 16 |
| 108 | Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017 , 152, 1975-1984.e8 | 13.3 | 219 |
| 107 | Decreased serum DNase1-activity in patients with autoimmune liver diseases. <i>Autoimmunity</i> , 2017 , 50, 125-132 | 3 | 4 |
| 106 | Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late?. <i>European Journal of Internal Medicine</i> , 2017 , 43, e48-e49 | 3.9 | 5 |
| 105 | Treatment of chronic hepatitis C with direct-acting antivirals in patients with ðhalassaemia major and advanced liver disease. <i>British Journal of Haematology</i> , 2017 , 178, 130-136 | 4.5 | 15 |
| 104 | The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017 , 66, 1444-1453 | 11.2 | 180 |
| 103 | Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. <i>European Journal of Internal Medicine</i> , 2017 , 42, 81-88 | 3.9 | 28 |
| 102 | Hepatocyte autotaxin expression promotes liver fibrosis and cancer. <i>Hepatology</i> , 2017 , 65, 1369-1383 | 11.2 | 90 |
| 101 | Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. <i>PLoS ONE</i> , 2017 , 12, e0182799 | 3.7 | 5 |
| 100 | Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever. <i>Journal of Rheumatology</i> , 2017 , 44, 102-109 | 4.1 | 33 |
| 99 | Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. <i>BMJ Case Reports</i> , 2017 , 2017, | 0.9 | 2 |

| | | | |
|----|---|------|-----|
| 98 | Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. <i>Annals of Gastroenterology</i> , 2017 , 30, 542-549 | 2.2 | 2 |
| 97 | Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017 , 9, e2017003 | 3.2 | 8 |
| 96 | Reply to "Further considerations in autoimmune hepatitis". <i>Journal of Hepatology</i> , 2016 , 64, 1458-9 | 13.4 | |
| 95 | PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016 , 64, 800-6 | 13.4 | 227 |
| 94 | Spontaneous Cirrhosis Regression in an IFN-beta-induced AIH-like Syndrome Following Drug Withdrawal: Art of Facts or Artifacts?. <i>European Journal of Case Reports in Internal Medicine</i> , 2016 , 3, 000396 | 13.6 | 2 |
| 93 | Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever. <i>BMJ Case Reports</i> , 2016 , 2016, | 0.9 | 2 |
| 92 | Molecular diagnostic testing for primary biliary cholangitis. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1001-10 | 3.8 | 20 |
| 91 | A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1035-47 | 6.1 | 58 |
| 90 | Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece. <i>International Journal of Infectious Diseases</i> , 2015 , 34, 46-50 | 10.5 | 19 |
| 89 | Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. <i>Journal of Translational Internal Medicine</i> , 2015 , 3, 43-50 | 3 | 88 |
| 88 | Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. <i>Liver International</i> , 2015 , 35, 660-72 | 7.9 | 31 |
| 87 | Oxidative stress and antioxidant status in patients with autoimmune liver diseases. <i>Redox Report</i> , 2015 , 20, 33-41 | 5.9 | 24 |
| 86 | On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , 2015 , 35, 1540-8 | 7.9 | 24 |
| 85 | Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015 , 24, 721-4 | 2.8 | 8 |
| 84 | Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2342-49.e1-2 | 6.9 | 41 |
| 83 | Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015 , 62, 363-70 | 13.4 | 124 |
| 82 | Spontaneous bacterial peritonitis: an unusual manifestation of brucellosis in a previous healthy male patient. <i>BMJ Case Reports</i> , 2015 , 2015, | 0.9 | 6 |
| 81 | Low Serum Hcpidin in Patients with Autoimmune Liver Diseases. <i>PLoS ONE</i> , 2015 , 10, e0135486 | 3.7 | 17 |

| | | | |
|----|--|------|-----|
| 80 | Efficacy of Interferon A-2b monotherapy in β -thalassemics with chronic hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2015 , 24, 189-96 | 1.4 | 4 |
| 79 | Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. <i>World Journal of Gastroenterology</i> , 2015 , 21, 60-83 | 5.6 | 89 |
| 78 | Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015 , 7, 1875-83 | 3.4 | 17 |
| 77 | Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , 2014 , 34, 1207-15 | 7.9 | 5 |
| 76 | Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. <i>Clinical and Experimental Medicine</i> , 2014 , 14, 121-31 | 4.9 | 46 |
| 75 | Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. <i>Annals of Hepatology</i> , 2014 , 13, 127-135 | 3.1 | 26 |
| 74 | Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , 2014 , 60, 87-97 | 11.2 | 159 |
| 73 | Individualization of chronic hepatitis C treatment according to the host characteristics. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2839-53 | 5.6 | 8 |
| 72 | Adipokines as mediators of endothelial function and atherosclerosis. <i>Atherosclerosis</i> , 2013 , 227, 216-21 | 3.1 | 95 |
| 71 | Use of TNF α antagonists in refractory AIH: revealing the unforeseen. <i>Journal of Hepatology</i> , 2013 , 59, 197-8 | 13.4 | 16 |
| 70 | Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. <i>Autoimmunity</i> , 2013 , 46, 471-9 | 3 | 32 |
| 69 | Review article: autoimmune hepatitis -- current management and challenges. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 887-913 | 6.1 | 109 |
| 68 | Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. <i>Journal of Hepatology</i> , 2013 , 59, 949-56 | 13.4 | 75 |
| 67 | Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?. <i>Annals of Hepatology</i> , 2013 , 12, 147-151 | 3.1 | 15 |
| 66 | Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. <i>World Journal of Hepatology</i> , 2013 , 5, 577-83 | 3.4 | 15 |
| 65 | Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. <i>World Journal of Hepatology</i> , 2013 , 5, 387-92 | 3.4 | 27 |
| 64 | Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?. <i>Annals of Hepatology</i> , 2013 , 12, 147-51 | 3.1 | 8 |
| 63 | Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. <i>Annals of Hepatology</i> , 2013 , 13, 127-35 | 3.1 | 14 |

| | | | |
|----|---|------|-----|
| 62 | Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?. <i>Liver International</i> , 2012 , 32, 544-53 | 7.9 | 41 |
| 61 | IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. <i>Clinica Chimica Acta</i> , 2012 , 413, 1683-8 | 6.2 | 12 |
| 60 | Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2 β -lactamase. <i>International Journal of Antimicrobial Agents</i> , 2012 , 39, 247-50 | 14.3 | 42 |
| 59 | Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012 , 36, 84-93 | 2.4 | 16 |
| 58 | Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon- α treatment. <i>Antiviral Therapy</i> , 2012 , 17, 305-12 | 1.6 | 20 |
| 57 | Metabolic acidosis during treatment of mushroom poisoning: a diagnostic pitfall. <i>Internal Medicine</i> , 2012 , 51, 1077-80 | 1.1 | 5 |
| 56 | Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4721-8 | 5.6 | 13 |
| 55 | Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. <i>Turkish Journal of Gastroenterology</i> , 2012 , 23, 560-8 | 1 | 17 |
| 54 | Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. <i>European Journal of Internal Medicine</i> , 2011 , 22, e155-7 | 3.9 | 7 |
| 53 | Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. <i>Journal of Hepatology</i> , 2011 , 55, 636-646 | 13.4 | 124 |
| 52 | Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. <i>Liver International</i> , 2011 , 31, 277-9 | 7.9 | 5 |
| 51 | Unusual cardiovascular complications of brucellosis presenting in two men: two case reports and a review of the literature. <i>Journal of Medical Case Reports</i> , 2011 , 5, 22 | 1.2 | 13 |
| 50 | Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. <i>Autoimmunity Reviews</i> , 2011 , 10, 389-96 | 13.6 | 69 |
| 49 | Peginterferon plus adefovir versus either drug alone for hepatitis delta. <i>New England Journal of Medicine</i> , 2011 , 364, 322-31 | 59.2 | 303 |
| 48 | Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. <i>Liver International</i> , 2010 , 30, 430-7 | 7.9 | 66 |
| 47 | Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. <i>Gastroenterology Research and Practice</i> , 2010 , 2010, | 2 | 3 |
| 46 | Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. <i>World Journal of Gastroenterology</i> , 2010 , 16, 225-31 | 5.6 | 28 |
| 45 | Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?. <i>Digestive and Liver Disease</i> , 2010 , 42, 807-12 | 3.3 | 49 |

| | | | |
|----|--|------|-----|
| 44 | PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010 , 35, 436-42 | 15.5 | 103 |
| 43 | Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , 2010 , 411, 411-5 | 6.2 | 16 |
| 42 | Occult hepatitis B virus infection in patients with autoimmune liver diseases. <i>Liver International</i> , 2009 , 29, 434-42 | 7.9 | 39 |
| 41 | Which level of immunosuppression is harmful for occult hepatitis B virus infection?: A million dollar answer. <i>Liver International</i> , 2009 , 29, 1127-1128 | 7.9 | 1 |
| 40 | Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. <i>European Journal of Internal Medicine</i> , 2009 , 20, 35-43 | 3.9 | 18 |
| 39 | Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. <i>International Journal of Infectious Diseases</i> , 2009 , 13, e157-60 | 10.5 | 21 |
| 38 | Spontaneous spondylodiscitis: presentation, risk factors, diagnosis, management, and outcome. <i>International Journal of Infectious Diseases</i> , 2009 , 13, 564-9 | 10.5 | 54 |
| 37 | Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 1220 | 2.2 | 21 |
| 36 | An immunocompetent patient presenting with severe septic arthritis due to <i>Ralstonia pickettii</i> identified by molecular-based assays: a case report. <i>Cases Journal</i> , 2009 , 2, 8125 | | 9 |
| 35 | Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: what is the message?. <i>Liver International</i> , 2008 , 28, 426-8 | 7.9 | 8 |
| 34 | Bone marrow findings in patients with autoimmune liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, e416-21 | 4 | 6 |
| 33 | Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2008 , 6, 855-9 | 5.5 | 7 |
| 32 | Severe pharyngitis in stockbreeders: an unusual presentation of brucellosis. <i>Occupational Medicine</i> , 2008 , 58, 305-7 | 2.1 | 9 |
| 31 | Molecular diagnostics of primary biliary cirrhosis. <i>Expert Opinion on Medical Diagnostics</i> , 2008 , 2, 621-34 | | 19 |
| 30 | Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2008 , 103, 605-14 | 0.7 | 45 |
| 29 | Could the 90s be a second childhood period? The case of Henoch-Schonlein purpura. <i>Age and Ageing</i> , 2008 , 37, 483 | 3 | |
| 28 | IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. <i>Journal of Clinical Immunology</i> , 2008 , 28, 501-11 | 5.7 | 33 |
| 27 | Autoimmune hepatitis: of host and pathogen. <i>Hepatology</i> , 2008 , 47, 2147-8 | 11.2 | 3 |

| | | | |
|----|---|------|------|
| 26 | Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008 , 48, 169-76 | 11.2 | 1166 |
| 25 | Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. <i>Hepatology</i> , 2007 , 45, 1583; author reply 1583-4 | 11.2 | 46 |
| 24 | Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art of facts or an artifact?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 454-5 | 4 | 20 |
| 23 | Primary biliary cirrhosis and Henoch-Schonlein purpura: report of two cases and review of the literature. <i>Liver International</i> , 2007 , 27, 280-3 | 7.9 | 16 |
| 22 | Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. <i>Liver International</i> , 2007 , 27, 1226-31 | 7.9 | 52 |
| 21 | How common are connective tissue disorders in patients with autoimmune hepatitis?. <i>Seminars in Arthritis and Rheumatism</i> , 2007 , 36, 332; author reply 333 | 5.3 | 6 |
| 20 | Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. <i>Journal of Clinical Immunology</i> , 2007 , 27, 378-87 | 5.7 | 47 |
| 19 | Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. <i>Journal of Autoimmune Diseases</i> , 2007 , 4, 2 | | 17 |
| 18 | The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. <i>Journal of Autoimmune Diseases</i> , 2007 , 4, 3 | | 45 |
| 17 | Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , 2007 , 380, 118-21 | 6.2 | 33 |
| 16 | Lack of association between appendectomy and primary biliary cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2006 , 41, 573-6 | 2.4 | 4 |
| 15 | Unexplained choroidal embolisation: remember the antiphospholipid syndrome. <i>Lancet, The</i> , 2006 , 368, 1936 | 4.0 | 3 |
| 14 | Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. <i>Clinica Chimica Acta</i> , 2006 , 373, 183-4; author reply 185 | 6.2 | 16 |
| 13 | Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. <i>Clinical Immunology</i> , 2006 , 119, 203-12 | 9 | 48 |
| 12 | Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. <i>Journal of Hepatology</i> , 2006 , 44, 848-55 | 13.4 | 19 |
| 11 | Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. <i>Experimental Biology and Medicine</i> , 2006 , 231, 1653-63 | 3.7 | 10 |
| 10 | Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2005 , 24, 251-60 | 15.5 | 41 |
| 9 | Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. <i>Journal of Autoimmune Diseases</i> , 2004 , 1, 2 | | 94 |

| | | | |
|---|---|------|----|
| 8 | Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. <i>European Journal of Clinical Investigation</i> , 2003 , 33, 161-8 | 4.6 | 56 |
| 7 | Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 35-42 | 2.2 | 36 |
| 6 | Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2000 , 12, 67-74 | 2.2 | 56 |
| 5 | Anti-neutrophil antibodies in chronic viral hepatitis. <i>Journal of Hepatology</i> , 1994 , 20, 561 | 13.4 | 11 |
| 4 | Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1994 , 6, 547-552 | 2.2 | 10 |
| 3 | Variants of Primary Biliary Cholangitis: An Updated Mini-Review6, 21-28 | | 4 |
| 2 | Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis | | 1 |
| 1 | ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients | | 1 |